Symbols

Symbols

LCTX

LCTX

Lineage Cell Therapeutics: A Viable Speculative Buy for Regenerative Medicine

Thursday Nov 06, 2025

Lineage Cell Therapeutics Extends Cash Runway into Q2 2027 with OpRegen Expansion and New Partnerships

Lineage Cell Therapeutics Q3 revenue up 34% YoY to $5.6 mln.

Monday Sep 29, 2025

HC Wainwright Affirms Buy Rating on Lineage Cell Therapeutics Amid Type 1 Diabetes Push

Friday Sep 26, 2025

Lineage Cell Therapeutics shares rise 8.71% intraday after Mesoblast's U.S. origin product designation.

Tuesday Sep 23, 2025

Lineage Cell Therapeutics Reports Positive 36-Month Phase 1/2a Results for RG6501 in OpRegen Trial

Saturday Sep 13, 2025

Lineage Cell Therapeutics Presents at H.C. Wainwright 27th Annual Global Investment Conference

Friday Sep 12, 2025

Lineage Cell Therapeutics Presents at H.C. Wainwright Annual Conference

Monday Sep 08, 2025

Lineage Cell Therapeutics shares fall 1.20% after-hours following the initiation of a new islet cell transplant program in Type 1 Diabetes.

Monday Sep 01, 2025

Lineage Cell Therapeutics Q2 Earnings Call: Progress Amid Financial Challenges.

Wednesday Aug 27, 2025

Lineage Cell Therapeutics Analyst Ratings: Bullish Sentiments, Average 12-Month Price Target at $3.4

Lineage Therap Partners with WDI for Hearing Loss Research: Unlocking $12M for Clinical Trials

Lineage Cell Therapeutics Bolstered by Strategic Partnerships and Promising Trial Results, Analyst Reiterates Buy Rating with $9.00 Price Target.

Lineage Cell Therapeutics Partners with William Demant Invest for Auditory Neuronal Cell Transplant Research

Lineage Cell: Boral Capital Raises PT to $2 from $1, Maintains Buy Rating

Lineage Cell Therapeutics Partners with William Demant Invest to Develop ReSonance for Hearing Loss

Tuesday Aug 26, 2025

Lineage Cell Therapeutics shares rise 8.12% intraday after partnering with William Demant for hearing loss treatment.

Thursday Aug 21, 2025

Lineage's 15-min chart shows MACD Death Cross and Bollinger Bands Narrowing

Thursday Aug 14, 2025

Boral Capital Raises Lineage Cell PT to $2 from $2

Wednesday Aug 13, 2025

Lineage Cell Therapeutics shares rise 1.49% intraday after beating Wall Street earnings expectations.